# Effect on Migraine Frequency of Combined Anti-oxidant Therapy: The MIGRANT Study.

> **NCT02629536** · PHASE3 · UNKNOWN · sponsor: **University of Notre Dame Australia** · enrollment: 90 (estimated)

## Conditions studied

- Migraine, Headaches

## Interventions

- **DRUG:** N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet

## Key facts

- **NCT ID:** NCT02629536
- **Lead sponsor:** University of Notre Dame Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2015-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02629536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02629536, "Effect on Migraine Frequency of Combined Anti-oxidant Therapy: The MIGRANT Study.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02629536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*